• 
• 
• 
• 
• 

2022

• An Electron-Deficient CpE Iridium(III) Catalyst: Synthesis, Characterization, and Application to Ether-Directed C-H Amidation.
  Tomita E, Kojima M, Nagashima Y, Tanaka K, Sugiyama H, Segawa Y, Furukawa A, Maenaka K, Maeda S, Yoshino T, Matsunaga S.
  Angew Chem Int Ed Engl. 2023 Mar 14:e202301259. doi: 10.1002/anie.202301259. Online ahead of print.
  PMID: 36918357
• Ready-to-Use-Type Lyophilized Lipid Nanoparticle Formulation for the Postencapsulation of Messenger RNA.
  Tanaka H, Hagiwara S, Shirane D, Yamakawa T, Sato Y, Matsumoto C, Ishizaki K, Hishinuma M, Chida K, Sasaki K, Yonemochi E, Ueda K, Higashi K, Moribe K, Tadokoro T, Maenaka K, Taneichi S, Nakai Y, Tange K, Sakurai Y, Akita H.
  ACS Nano. 2023 Feb 14;17(3):2588-2601. doi: 10.1021/acsnano.2c10501. Epub 2023 Jan 31.
  PMID: 36719091
• Corrigendum: Intraocular human cytomegaloviruses of ocular diseases are distinct from those of viremia and are capable of escaping from innate and adaptive immunity by exploiting HLA-E-mediated peripheral and central tolerance.
  Shirane M, Yawata N, Motooka D, Shibata K, Khor SS, Omae Y, Kaburaki T, Yanai R, Mashimo H, Yamana S, Ito T, Hayashida A, Mori Y, Numata A, Murakami Y, Fujiwara K, Ohguro N, Hosogai M, Akiyama M, Hasegawa E, Paley M, Takeda A, Maenaka K, Akashi K, Yokoyama WM, Tokunaga K, Yawata M, Sonoda KH.
  Front Immunol. 2023 Jan 5;13:1124440. doi: 10.3389/fimmu.2022.1124440. eCollection 2022.
  PMID: 36685570
• Intraocular human cytomegaloviruses of ocular diseases are distinct from those of viremia and are capable of escaping from innate and adaptive immunity by exploiting HLA-E-mediated peripheral and central tolerance
  Shirane M, Yawata N, Motooka D, Shibata K, Khor SS, Omae Y, Kaburaki T, Yanai R, Mashimo H, Yamana S, Ito T, Hayashida A, Mori Y, Numata A, Murakami Y, Fujiwara K, Ohguro N, Hosogai M, Akiyama M, Hasegawa E, Paley M, Takeda A, Maenaka K, Akashi K, Yokoyama WM, Tokunaga K, Yawata M, Sonoda KH.
  Front Immunol. 2022 Oct 19;13:1008220. doi: 10.3389/fimmu.2022.1008220. eCollection 2022.
  PMID: 36341392
• Dihydromaniwamycin E, a Heat-Shock Metabolite from Thermotolerant Streptomyces sp. JA74, Exhibiting Antiviral Activity against Influenza and SARS-CoV-2 Viruses.
  Saito S, Funayama K, Kato W, Okuda M, Kawamoto M, Matsubara T, Sato T, Sato A, Otsuguro S, Sasaki M, Orba Y, Sawa H, Maenaka K, Shindo K, Imoto M, Arai MA.
  J Nat Prod. 2022 Nov 25;85(11):2583-2591. doi: 10.1021/acs.jnatprod.2c00550. Epub 2022 Oct 12.
  PMID: 36223390
• Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant.
  Saito A, Tamura T, Zahradnik J, Deguchi S, Tabata K, Anraku Y, Kimura I, Ito J, Yamasoba D, Nasser H, Toyoda M, Nagata K, Uriu K, Kosugi Y, Fujita S, Shofa M, Monira Begum M, Shimizu R, Oda Y, Suzuki R, Ito H, Nao N, Wang L, Tsuda M, Yoshimatsu K, Kuramochi J, Kita S, Sasaki-Tabata K, Fukuhara H, Maenaka K, Yamamoto Y, Nagamoto T, Asakura H, Nagashima M, Sadamasu K, Yoshimura K, Ueno T, Schreiber G, Takaori-Kondo A; Genotype to Phenotype Japan (G2P-Japan) Consortium; Shirakawa K, Sawa H, Irie T, Hashiguchi T, Takayama K, Matsuno K, Tanaka S, Ikeda T, Fukuhara T, Sato K.
  Cell Host Microbe. 2022 Nov 9;30(11):1540-1555.e15. doi: 10.1016/j.chom.2022.10.003. Epub 2022 Oct
  PMID: 36272413
• High-Throughput Screening Assay Identifies Berberine and Mubritinib as Neuroprotection Drugs for Spinal Cord Injury via Blood-Spinal Cord Barrier Protection.
  Suzuki Y, Nakagawa S, Endo T, Sotome A, Yuan R, Asano T, Otsuguro S, Maenaka K, Iwasaki N, Kadoya K.
  Neurotherapeutics. 2022 Oct;19(6):1976-1991. doi: 10.1007/s13311-022-01310-y. Epub 2022 Sep 30.
  PMID: 36178590
• Hydrophobic Alpha-Helical Short Peptides in Overlapping Reading Frames of the Coronavirus Genome.
  Okura T, Shirato K, Kakizaki M, Sugimoto S, Matsuyama S, Tanaka T, Kume Y, Chishiki M, Ono T, Moriishi K, Sonoyama M, Hosoya M, Hashimoto K, Maenaka K, Takeda M.
  Pathogens. 2022 Aug 3;11(8):877. doi: 10.3390/pathogens11080877.
  PMID: 36014999
• Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas.
  Chiba M, Shimono J, Ishio T, Takei N, Kasahara K, Ogasawara R, Ara T, Goto H, Izumiyama K, Otsuguro S, Perera LP, Hasegawa H, Maeda M, Hashino S, Maenaka K, Teshima T, Waldmann TA, Yang Y, Nakagawa M.
  Blood. 2022 Nov 3;140(18):1951-1963. doi: 10.1182/blood.2022015646.
  PMID: 35921533
• Structure of the human galanin receptor 2 bound to galanin and Gq reveals the basis of ligand specificity and how binding affects the G-protein interface.
  Heo Y, Ishimoto N, Jeon YE, Yun JH, Ohki M, Anraku Y, Sasaki M, Kita S, Fukuhara H, Ikuta T, Kawakami K, Inoue A, Maenaka K, Tame JRH, Lee W, Park SY.
  PLoS Biol. 2022 Aug 1;20(8):e3001714. doi: 10.1371/journal.pbio.3001714. eCollection 2022 Aug.
  PMID: 35913979
• Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants.
  Ozawa T, Tani H, Anraku Y, Kita S, Igarashi E, Saga Y, Inasaki N, Kawasuji H, Yamada H, Sasaki SI, Somekawa M, Sasaki J, Hayakawa Y, Yamamoto Y, Morinaga Y, Kurosawa N, Isobe M, Fukuhara H, Maenaka K, Hashiguchi T, Kishi H, Kitajima I, Saito S, Niimi H.
  MAbs. 2022 Jan-Dec;14(1):2072455. doi: 10.1080/19420862.2022.2072455.
  PMID: 35543180
• Impact of Micropolymorphism Outside the Peptide Binding Groove in the Clinically Relevant Allele HLA-C*14 on T Cell Responses in HIV-1 Infection.
  Chikata T, Paes W, Kuse N, Partridge T, Gatanaga H, Zhang Y, Kuroki K, Maenaka K, Ternette N, Oka S, Borrow P, Takiguchi M.
  J Virol. 2022 May 25;96(10):e0043222. doi: 10.1128/jvi.00432-22. Epub 2022 Apr 27.
  PMID: 35475667
• Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity.
  Maruhashi T, Sugiura D, Okazaki IM, Shimizu K, Maeda TK, Ikubo J, Yoshikawa H, Maenaka K, Ishimaru N, Kosako H, Takemoto T, Okazaki T.
  Immunity. 2022 May 10;55(5):912-924.e8. doi: 10.1016/j.immuni.2022.03.013. Epub 2022 Apr 11.
  PMID: 35413245

• 免疫受容体の弱く速い結合を介したリガンド認識機構
  渡邊紘士、黒木喜美子、前仲勝実
  Drug Delivery System
• SARS-CoV-2感染と中和抗体開発
  安楽佑樹, 喜多俊介, 福原秀雄, 前仲勝実
  月刊臨床免疫・アレルギー科 77(5) 2022年

• 
•